|
interprofessional education |
44 |
|
social interaction anxiety |
40 |
|
partnership model |
28 |
|
hepatocellular carcinoma |
22 |
|
construct validation |
16 |
|
berberine |
15 |
|
oxidative stress |
10 |
|
apoptosis |
9 |
|
autophagy |
9 |
|
gut microbiota |
9 |
|
traditional chinese medicine |
9 |
|
coptidis rhizoma |
8 |
|
diabetic retinopathy |
8 |
|
mir-23a |
8 |
|
chinese medicine |
7 |
|
covid-19 |
7 |
|
genipin |
7 |
|
herbal medicine |
7 |
|
medicine, chinese traditional |
7 |
|
review |
7 |
|
tumor growth inhibition |
7 |
|
animal bile |
6 |
|
antimetastasis |
6 |
|
bcl-2/beclin-1 |
6 |
|
bile acids |
6 |
|
cachexia |
6 |
|
cancer diagnosis |
6 |
|
cancer metastasis |
6 |
|
cancer therapy |
6 |
|
cytotoxicity |
6 |
|
diagnosis |
6 |
|
drug discovery |
6 |
|
f-actin |
6 |
|
gardenia |
6 |
|
gegen qinlian decoction |
6 |
|
he-ying-qing-re formula |
6 |
|
high performance liquid chromatography-evaporative light scattering detector system |
6 |
|
immune response |
6 |
|
iridoid glycosides |
6 |
|
iridoids |
6 |
|
medical sciences |
6 |
|
meta-analysis |
6 |
|
metabolomics |
6 |
|
metastasis |
6 |
|
micrornas |
6 |
|
mtor |
6 |
|
natural products |
6 |
|
nf-κb |
6 |
|
obesity |
6 |
|
prognosis |
6 |
|
ro/rock signaling |
6 |
|
tumor microenvironment |
6 |
|
type 2 diabetes mellitus |
6 |
|
animal experiment |
5 |
|
bile - chemistry |
5 |
|
cancer |
5 |
|
cancer cell culture |
5 |
|
cell invasion |
5 |
|
cell migration |
5 |
|
cell motility |
5 |
|
chinese herbal antioxidants |
5 |
|
cholagogues and choleretics - pharmacology - therapeutic use |
5 |
|
circulating tumor cells |
5 |
|
clinical trials |
5 |
|
coptidis rhizoma aqueous extract |
5 |
|
cytokine storm |
5 |
|
diabetes |
5 |
|
dna damage |
5 |
|
etoposide |
5 |
|
flavonoid |
5 |
|
gallbladder |
5 |
|
gut–liver axis |
5 |
|
herbal medicines |
5 |
|
immunotherapy |
5 |
|
inflammation |
5 |
|
interprofessional attitudes |
5 |
|
ire1α |
5 |
|
liver cancer |
5 |
|
liver diseases |
5 |
|
lysosomal proteolysis |
5 |
|
microrna |
5 |
|
mir-21 |
5 |
|
nascent protein synthesis |
5 |
|
network pharmacology |
5 |
|
organ protection |
5 |
|
organotherapy |
5 |
|
polysaccharides |
5 |
|
saponins |
5 |
|
timosaponin aiii |
5 |
|
topoisomerase 1 |
5 |
|
tumor |
5 |
|
tumour-associated macrophage |
5 |
|
virus infection |
5 |
|
xiap |
5 |
|
akt/mtor |
4 |
|
alcoholic liver injury |
4 |
|
anti-cancer |
4 |
|
antioxidant |
4 |
|
beige cell |
4 |
|
cancer stem cells |
4 |
|
chinese medicinal herbs |
4 |
|
chinese medicines |
4 |
|
complementary and alternative medicines |
4 |
|
coptidis rhizome aqueous extract |
4 |
|
cyclin d1 |
4 |
|
diabetic kidney disease |
4 |
|
diabetic nephropathy |
4 |
|
endoplasmic reticulum stress |
4 |
|
eukaryotic elongation factor 2 |
4 |
|
foods |
4 |
|
granulocytic‐myeloid‐derived suppressor cell‐like population |
4 |
|
hepatotoxicity |
4 |
|
hif-1α |
4 |
|
huanglian jiedu decoction |
4 |
|
insulin |
4 |
|
lef1 |
4 |
|
leptin |
4 |
|
mangiferin |
4 |
|
medicinal plants |
4 |
|
molecular targets |
4 |
|
nafld |
4 |
|
oncology |
4 |
|
patent |
4 |
|
phytotherapy |
4 |
|
retinal degeneration |
4 |
|
rgc apoptosis |
4 |
|
signaling pathway |
4 |
|
tumor angiogenesis |
4 |
|
ubiquitinated-dependent proteolysis |
4 |
|
vascular endothelial growth factor |
4 |
|
vegf |
4 |
|
white adipocyte |
4 |
|
wnt signalling |
4 |
|
wt1 |
4 |
|
β-trcp |
4 |
|
5-fluorouracil |
3 |
|
acsl4 |
3 |
|
acute alcoholic liver damage |
3 |
|
akkermansia muciniphila |
3 |
|
alternative |
3 |
|
alternative therapy |
3 |
|
alzheimer’s disease |
3 |
|
ampk |
3 |
|
amyloid-beta precursor protein |
3 |
|
anti-inflammatory |
3 |
|
anti-oxidative |
3 |
|
anti-tumor immunity |
3 |
|
anticancer drugs |
3 |
|
antimetastasis drugs |
3 |
|
antineoplastic agent |
3 |
|
antineoplastic agents, phytogenic - adverse effects - pharmacology - therapeutic use |
3 |
|
antineoplastic agents, phytogenic - adverse effects - therapeutic use |
3 |
|
artificial intelligence |
3 |
|
bear bile |
3 |
|
berberine - adverse effects - pharmacology - therapeutic use |
3 |
|
bioinformatics analysis |
3 |
|
biomarker |
3 |
|
biomarkers |
3 |
|
bl02 |
3 |
|
blended learning |
3 |
|
botanical drug pairs |
3 |
|
breast cancer |
3 |
|
cancer drug resistance |
3 |
|
cancer drug sensitivity |
3 |
|
cancer prognosis |
3 |
|
cancer progression |
3 |
|
cancer surveillance |
3 |
|
cancer treatment |
3 |
|
cancer-related fatigue |
3 |
|
case study |
3 |
|
cell-free dna |
3 |
|
chemoprevention |
3 |
|
chemotherapy |
3 |
|
chemotherapy-induced diarrhea |
3 |
|
chinese herbal |
3 |
|
chinese herbal medicine |
3 |
|
chinese herbal medicine formula |
3 |
|
chinese medicine herbal formulae |
3 |
|
chronic diseases |
3 |
|
chronic liver disease |
3 |
|
circrnas |
3 |
|
circulating tumor cell (ctc) |
3 |
|
circulating tumor dna |
3 |
|
colorectal cancer |
3 |
|
comparative study |
3 |
|
crgs |
3 |
|
crispr-cas9 |
3 |
|
crispr/cas9 screens |
3 |
|
cuproptosis |
3 |
|
cxcl2 |
3 |
|
diabetes mellitus |
3 |
|
diabetic complications |
3 |
|
diagnosis and therapy |
3 |
|
disease detection |
3 |
|
disease progression |
3 |
|
disease treating & preventing |
3 |
|
drug discovery and development |
3 |
|
drug reaction |
3 |
|
drug response |
3 |
|
drugs, chinese herbal - adverse effects - pharmacology - therapeutic use |
3 |
|
e-learning |
3 |
|
early detection |
3 |
|
eef2 |
3 |
|
efficacy |
3 |
|
egfr |
3 |
|
endothelial cells |
3 |
|
endothelial dysfunctions |
3 |
|
epigallocatechin gallate |
3 |
|
ets1 |
3 |
|
exogenous micrornas |
3 |
|
exosomal lncrnas |
3 |
|
exosome |
3 |
|
experimental models |
3 |
|
fak |
3 |
|
fak inhibitors |
3 |
|
fatty acid oxidation |
3 |
|
fatty acids |
3 |
|
fatty liver |
3 |
|
ferroptosis |
3 |
|
fibrosis |
3 |
|
field trip |
3 |
|
gallic acid |
3 |
|
gc |
3 |
|
genomics - methods |
3 |
|
gentiana rhodantha |
3 |
|
gerbera anandria |
3 |
|
gout |
3 |
|
gpc2 |
3 |
|
granulocytic myeloid-derived suppressor cells |
3 |
|
green tea |
3 |
|
growth inhibition |
3 |
|
gut microbiome |
3 |
|
haic |
3 |
|
hamp |
3 |
|
health research |
3 |
|
hepatic tumorigenesis |
3 |
|
hepatobiliary diseases |
3 |
|
hepatocellular carcinoma (hcc) |
3 |
|
hepatoprotection |
3 |
|
herb medicine |
3 |
|
huanglian |
3 |
|
human cancers |
3 |
|
hyperuricemia |
3 |
|
hyperuricemic nephropathy |
3 |
|
il-6 |
3 |
|
immune cells |
3 |
|
immune suppression |
3 |
|
immunity |
3 |
|
immunization |
3 |
|
immunotherapies |
3 |
|
inflammation-regulated cell death |
3 |
|
inhibitor of differentiation/dna binding 1 |
3 |
|
insulin resistance |
3 |
|
irinotecan |
3 |
|
leaky gut |
3 |
|
lianhua qingwen capsule |
3 |
|
library screening |
3 |
|
linc01056 |
3 |
|
lipid metabolism |
3 |
|
lipid modulation |
3 |
|
lipolysis |
3 |
|
liquid biopsy |
3 |
|
liver fibrosis |
3 |
|
liver neoplasms |
3 |
|
liver transplantation |
3 |
|
lncrnas |
3 |
|
local ablation |
3 |
|
long non-coding rna |
3 |
|
machine learning |
3 |
|
materia medica |
3 |
|
mechanisms of anticancer action |
3 |
|
melatonin |
3 |
|
metabolic diseases |
3 |
|
methylation |
3 |
|
microvesicle |
3 |
|
mind–body intervention |
3 |
|
mip1γ/ccr1 axis |
3 |
|
mir-23a-3p |
3 |
|
mmp-2 |
3 |
|
molecular docking-guided bioactive ingredient identification |
3 |
|
monosodium urate crystal |
3 |
|
mulberry twig alkaloids |
3 |
|
multi-component chinese medicine formula |
3 |
|
multi-pathways |
3 |
|
multiple parallel hits |
3 |
|
muscle atrophy |
3 |
|
natural compounds |
3 |
|
neoplasms - drug therapy |
3 |
|
netosis |
3 |
|
network analysis |
3 |
|
network meta-analysis |
3 |
|
neutrophil extracellular traps |
3 |
|
new technologies |
3 |
|
non-alcoholic fatty liver disease |
3 |
|
non-coding rnas |
3 |
|
nonalcoholic fatty liver disease |
3 |
|
nonalcoholic steatohepatitis |
3 |
|
nsclc |
3 |
|
nutrition therapy |
3 |
|
p53 |
3 |
|
pan-cancer |
3 |
|
panax notoginseng |
3 |
|
pancreatic adenocarcinoma |
3 |
|
pard3 |
3 |
|
pattern recognition |
3 |
|
pd-1 |
3 |
|
phenolic acids |
3 |
|
physical exercise |
3 |
|
plant extracts - adverse effects - therapeutic use |
3 |
|
pns |
3 |
|
post-translational modification |
3 |
|
potassium oxonate |
3 |
|
pparα |
3 |
|
probiotics |
3 |
|
prognostic model |
3 |
|
proliferative diabetic retinopathy |
3 |
|
qigong |
3 |
|
radix scutellariae |
3 |
|
rap1/cdc42 |
3 |
|
recurrence |
3 |
|
renal carcinoma |
3 |
|
retina macrophages |
3 |
|
safety |
3 |
|
sars-cov-2 |
3 |
|
serological biomarkers |
3 |
|
side effect |
3 |
|
sonic hedgehog |
3 |
|
sorafenib |
3 |
|
sorafenib resistance |
3 |
|
src |
3 |
|
steatosis |
3 |
|
subtypes |
3 |
|
sumoylation |
3 |
|
surgical resection |
3 |
|
systematic review |
3 |
|
tace |
3 |
|
tai chi |
3 |
|
tang-ning-tong-luo |
3 |
|
target identification |
3 |
|
targeted therapies |
3 |
|
therapeutic option |
3 |
|
tissue biopsy |
3 |
|
tumor response |
3 |
|
tumor-associated neutrophils |
3 |
|
tumor-derived vesicles |
3 |
|
tumour microenvironment |
3 |
|
type i interferon |
3 |
|
tyrosine kinase inhibitor |
3 |
|
tyrosine kinase inhibitors |
3 |
|
uric acid |
3 |
|
vasculature |
3 |
|
wnt/β-catenin pathway |
3 |
|
yap |
3 |
|
yoga |
3 |
|
2,3,5,4′-tetrahydroxystilbene-2-o-β-d-glucoside |
2 |
|
aconitine |
2 |
|
aconitum |
2 |
|
adaptive immunity |
2 |
|
adipogenesis |
2 |
|
adjuvant therapie |
2 |
|
advanced glycation end products |
2 |
|
alanine transaminase - blood |
2 |
|
alcoholic liver disease (ald) |
2 |
|
all-cause mortality |
2 |
|
allergy |
2 |
|
amp-activated protein kinases - metabolism |
2 |
|
angiogenesis |
2 |
|
animals |
2 |
|
anti-liver fibrosis |
2 |
|
anti-oxidant agent |
2 |
|
anti-tumor activity |
2 |
|
anticancer |
2 |
|
antioxidants |
2 |
|
apoptosis - drug effects |
2 |
|
aspartate aminotransferases - blood |
2 |
|
asthma |
2 |
|
atg9b |
2 |
|
autophagic cell death |
2 |
|
autophagosome |
2 |
|
baicalein |
2 |
|
baicalin |
2 |
|
berberine - therapeutic use. |
2 |
|
betulinic acid |
2 |
|
biliary cancer |
2 |
|
biological aging |
2 |
|
blood-retina-barrier breakdown |
2 |
|
cancer chemotherapy |
2 |
|
cancer immunotherapy |
2 |
|
cancer management |
2 |
|
cancer metabolism |
2 |
|
carbon tetrachloride |
2 |
|
carcinogenesis |
2 |
|
carcinoma, hepatocellular - drug therapy - genetics - metabolism - pathology |
2 |
|
caspase 3 - metabolism |
2 |
|
ccs |
2 |
|
cell activation |
2 |
|
cell aging |
2 |
|
cell apoptosis |
2 |
|
cell death |
2 |
|
cell proliferation and survival |
2 |
|
chemoresistance |
2 |
|
chemosensitizer |
2 |
|
chemotaxis |
2 |
|
chemotherapy induced nausea and vomiting |
2 |
|
chinese herbal medicines |
2 |
|
chronic liver damage |
2 |
|
chronic obstructive pulmonary disease |
2 |
|
clinical application |
2 |
|
clinical efficacy |
2 |
|
cohort study |
2 |
|
colorecal cancer |
2 |
|
combination strategy |
2 |
|
complementary medicine |
2 |
|
coptis - therapeutic use. |
2 |
|
coriolus versicolor |
2 |
|
coxsackievirus b3 |
2 |
|
cystic fibrosis |
2 |
|
detoxification |
2 |
|
diabetic retinopathy (糖尿病視網膜病變) |
2 |
|
dna fragmentation - drug effects |
2 |
|
drug efficacy |
2 |
|
drug processing |
2 |
|
drug resistance |
2 |
|
drug resistance of hepatocellular carcinoma |
2 |
|
drug-induced liver injury - blood - drug therapy - pathology |
2 |
|
drugs, chinese herbal - analysis - therapeutic use |
2 |
|
electroacupuncture |
2 |
|
emt |
2 |
|
epi-drugs |
2 |
|
epigenetic inhibitors |
2 |
|
epigenetic modification |
2 |
|
er stress |
2 |
|
erk1/2 inhibition |
2 |
|
experimental study |
2 |
|
fangchinoline |
2 |
|
frailty |
2 |
|
function herbal formula |
2 |
|
gastrointestinal toxicity |
2 |
|
glucose–alanine cycle |
2 |
|
gpt1 |
2 |
|
hcc |
2 |
|
hepatic carcinogenesis |
2 |
|
hepatocytes - drug effects - metabolism |
2 |
|
hepatoprotective |
2 |
|
hepatoprotective chinese herbal medicines |
2 |
|
hepatoprotective effect |
2 |
|
herb-induced liver injury |
2 |
|
herbal products |
2 |
|
huachansu capsules |
2 |
|
human cancer |
2 |
|
huvec |
2 |
|
hypoxia-inducible factor-1 |
2 |
|
immunosuppression |
2 |
|
in vivo crispr/cas9 screen |
2 |
|
inhibitor |
2 |
|
innate immunity |
2 |
|
intestinal barrier |
2 |
|
intracellular targets |
2 |
|
intrinsic and extrinsic pathways |
2 |
|
invasion |
2 |
|
ischemic stroke |
2 |
|
jnk |
2 |
|
kegg pathway |
2 |
|
l-lactate |
2 |
|
lactate dehydrogenase |
2 |
|
limitations |
2 |
|
lipid peroxidation |
2 |
|
lipid synthesis |
2 |
|
liver - cancer - treatment. |
2 |
|
liver cirrhosis - drug therapy |
2 |
|
liver disease |
2 |
|
liver injury |
2 |
|
liver neoplasms - drug therapy - genetics - metabolism - pathology |
2 |
|
lung diseases |
2 |
|
macrophage |
2 |
|
macular edema (黃斑水腫) |
2 |
|
male |
2 |
|
map kinase signaling system - drug effects |
2 |
|
mechanism of action |
2 |
|
metabolic reprogramming |
2 |
|
microangiopathy (微血管病變) |
2 |
|
migration |
2 |
|
mir-3689a-3p |
2 |
|
mtor pathway |
2 |
|
mts derivatives |
2 |
|
multi-component |
2 |
|
national health and nutrition examination survey |
2 |
|
network pharmacolog |
2 |
|
non-cell-autonomous drug resistance |
2 |
|
nuclear proteins - genetics - metabolism |
2 |
|
nyg |
2 |
|
oroxylin a |
2 |
|
osteoprotegerin |
2 |
|
pai-1 |
2 |
|
pancreatic cancer |
2 |
|
patents as topic |
2 |
|
pck-1 |
2 |
|
pharmacological evaluation |
2 |
|
plant extracts - therapeutic use |
2 |
|
plants, medicinal |
2 |
|
polarization |
2 |
|
polysaccharide |
2 |
|
postoperative recurrence |
2 |
|
pparɤ |
2 |
|
pparγ |
2 |
|
prediabetes |
2 |
|
programmed cell death |
2 |
|
radix polygoni multiflori |
2 |
|
radix salviae miltiorrhizae |
2 |
|
rats |
2 |
|
rats, sprague-dawley |
2 |
|
retinal vasculature degeneration |
2 |
|
salvia miltiorrhiza |
2 |
|
saw palmetto |
2 |
|
schisandra chinensis |
2 |
|
scutallariae baicalensis |
2 |
|
scutellaria baicalensis |
2 |
|
selenium |
2 |
|
sestrin2 |
2 |
|
side effects |
2 |
|
significant pathways |
2 |
|
source of drug discovery |
2 |
|
synthesis |
2 |
|
targeted therapy |
2 |
|
tcm |
2 |
|
tetrandrine |
2 |
|
toxicology |
2 |
|
traditional chinese medicine (中藥) |
2 |
|
traditional chinese medicines |
2 |
|
traditional medicine |
2 |
|
tumor suppressor protein p53 - metabolism |
2 |
|
tumor-associated macrophage |
2 |
|
tumour-derived exosome |
2 |
|
upa |
2 |
|
wogonin |
2 |
|
wuweizi |
2 |
|
xiao-chai-hu-tang |
2 |
|
yinchenhao decoction |
2 |
|
zuojin pill |
2 |
|
acridine |
1 |
|
active surveillance |
1 |
|
adult stem cells |
1 |
|
adverse events |
1 |
|
akt/mtor signaling |
1 |
|
alternative medicine (cam) |
1 |
|
analgesic |
1 |
|
anti-cancer (anticancer) drugs |
1 |
|
antrodia cinnamomea polysaccharide |
1 |
|
apoptotic pathways |
1 |
|
bioactive compound |
1 |
|
bone cancer pain |
1 |
|
botanical drug |
1 |
|
cancers |
1 |
|
clusterin |
1 |
|
complex |
1 |
|
cordycepin |
1 |
|
degradation |
1 |
|
differentiation |
1 |
|
disease |
1 |
|
drug design |
1 |
|
drugs |
1 |
|
epidemiology |
1 |
|
epigenetic mechanisms |
1 |
|
epigenetics |
1 |
|
exosomes |
1 |
|
fungi |
1 |
|
gastric cancer |
1 |
|
glomerulonephritis |
1 |
|
her2 |
1 |
|
immune resistance |
1 |
|
immunity-enhancement |
1 |
|
immunoregulatory |
1 |
|
invasion and metastasis |
1 |
|
jia-yuan-qing pill (jyqp) |
1 |
|
long noncoding rnas |
1 |
|
lsd1 |
1 |
|
macrophage polarization |
1 |
|
mechanisms |
1 |
|
medical food |
1 |
|
molecular mechanism |
1 |
|
natural product |
1 |
|
neddylation |
1 |
|
nuclear factor kappa b |
1 |
|
nutraceuticals |
1 |
|
pd-l1 |
1 |
|
polysaccharides of irpex lacteus fr. |
1 |
|
post-covid |
1 |
|
post-translational modifications |
1 |
|
proliferation |
1 |
|
proliferation and survival |
1 |
|
protacs |
1 |
|
protein degrader |
1 |
|
protein homeostasis |
1 |
|
regulation mechanisms |
1 |
|
resistance |
1 |
|
russula griseocarnosa polysaccharide |
1 |
|
self-renewal |
1 |
|
stemness |
1 |
|
structure |
1 |
|
t cell differentiation |
1 |
|
targets |
1 |
|
therapeutic advance |
1 |
|
therapy resistance |
1 |
|
tumor micreoenvironment (tme) |
1 |
|
ube2m |
1 |
|
usp7 |
1 |
